Eli Lilly has sued the FDA over the classification of its investigational glucagon-like peptide-1 (GLP-1) drug, retatrutide, arguing that the agency improperly classified the product as a drug rather than as a biological product.
It’s one of multiple legal and regulatory strategies that GLP-1 manufacturers are aggressively pursuing to stop compounding of the lucrative medications, said legal experts during a recent webinar sponsored by the healthcare law firm Frier